Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models
| Autor: | Guillermo Villa, Milton C. Weinstein, Kelly Fust, Qing Gu, Xiaoyan Li, Spiros Tzivelekis, Gary H. Lyman, Michael Maschio, Anju Parthan |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
medicine.medical_specialty Side effect Cost effectiveness Cost-Benefit Analysis medicine.medical_treatment Antineoplastic Agents 03 medical and health sciences 0302 clinical medicine Neoplasms Internal medicine Granulocyte Colony-Stimulating Factor Secondary Prevention medicine Humans Pharmacology (medical) 030212 general & internal medicine Intensive care medicine Febrile Neutropenia Myelosuppressive Chemotherapy Chemotherapy business.industry Health Policy Cancer General Medicine medicine.disease Colony-stimulating factor Chemotherapy regimen Primary Prevention Models Economic 030220 oncology & carcinogenesis business Febrile neutropenia |
| Zdroj: | Expert Review of Pharmacoeconomics & Outcomes Research. 17:39-52 |
| ISSN: | 1744-8379 1473-7167 |
| DOI: | 10.1080/14737167.2017.1276829 |
| Popis: | Introduction: We reviewed the evolution of the methods used in cost-effectiveness analyses of granulocyte colony-stimulating factors (G-CSFs) in the primary and secondary prevention of febrile neutropenia (FN) in patients receiving myelosuppressive cancer chemotherapy.Areas covered: FN is a side effect of myelosuppressive chemotherapy associated with significant morbidity, mortality, and costs. The risk of FN may depend on the drugs used within a chemotherapy regimen, and an FN event may cause chemotherapy dose reductions or delays in subsequent cycles.Expert commentary: More recent pharmacoeconomic models have reflected these clinical observations by modeling sequential chemotherapy regimens to account for FN risk on a per-cycle basis, and by accounting for chemotherapy dose reductions and consequent survival losses. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|